Physician profile
Jay M Winner
NPI 1689770687
$1,570.05
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $565 · 2021: $35.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $251.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $224.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $208.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $183.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $106.86 | 2019-2020 | |
| Lilly USA, LLC | $104.63 | 2019-2020 | |
| Pfizer INC. | $97.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.69 | 2019-2020 | |
| Allergan, INC. | $87.93 | 2019-2020 | |
| Amarin Pharma, INC. | $37.39 | 2019-2020 | |
| Sanofi Pasteur INC. | $37.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.94 | 2019 | |
| Amgen INC. | $22.19 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.41 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.86 | 2019 | |
| Abbvie INC. | $12.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Winner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.